Close Menu

NEW YORK (GenomeWeb) – Cancer Genetics said after the close of the market on Monday that its fourth quarter revenues rose 4 percent year over year, falling short of the consensus Wall Street estimate.

For the three months ended Dec. 31, 2017, the firm posted $7.5 million in total revenues, up from $7.2 million a year ago. On average, Wall Street had expected $9.2 million in revenues.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

A new analysis finds that nearly half the late-stage clinical trials sponsored by a US National Cancer Institute program influence patient care.

Technology Review reports that sickle cell patients are optimistic about gene editing to treat their disease, but are worried about how available it will be.

The owner of the GEDmatch website tells CBS12 he is considering charging law enforcement a fee to use the site.

In Nature this week: babies born by caesarean section are more likely to have altered gut microbiota profiles, and more.